Androgen deprivation therapy for localized and nonmetastatic prostate cancer: Too much of a good thing?

European Urology

Volumn 61, Issue 6, 2012, Pages 1129-1130

  Konijeti, Ramdev ^a   Kibel, Adam S ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN DEPRIVATION THERAPY; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CARDIOVASCULAR RISK; DISEASE COURSE; HIGH RISK PATIENT; HUMAN; NOTE; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RISK ASSESSMENT;

EID: 84860313706     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2012.03.002     Document Type: Editorial

References (10)

1. A.L. Potosky, B.B. Reeve, and L.X. Clegg Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy J Natl Cancer Inst 94 2002 430 437 (Pubitemid 34285092)
2. J.C. Hu, S.B. Williams, A.J. O'Malley, M.R. Smith, P.L. Nguyen, and N.L. Keating Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism Eur Urol 61 2012 1119 1128
3. P.L. Nguyen, Y. Je, and F.A.B. Schutz Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer JAMA 306 2011 2359 2366
4. M.V. Van Hemelrijck, J. Adolfsson, and H. Garmo Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden Lancet Oncol 11 2010 450 458
5. C. Huggins, R.E. Stevens, and C.V. Hodges Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of the prostate gland Arch Surg 43 1941 209 223
6. M. Bolla, G. Van Tienhoven, and P. Warde External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study Lancet Oncol 11 2010 1066 1073
7. J.W. Moul, H. Wu, and L. Sun Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy J Urol 171 2004 1141 1147 (Pubitemid 38327544)
8. G.L. Lu-Yao, P.C. Albertsen, and D.F. Moore Survival following primary androgen deprivation therapy among men with localized prostate cancer JAMA 300 2008 173 181 (Pubitemid 351969301)
9. V. Pagliarulo, S. Bracarda, and M.A. Eisenberger Contemporary role of androgen deprivation therapy for prostate cancer Eur Urol 61 2012 11 25
10. V.B. Shahinian, Y. Kuo, and S.M. Gilbert Reimbursement policy and androgen-deprivation therapy for prostate cancer N Engl J Med 363 2010 1822 1832